Q1 Earnings Forecast for DWTX Issued By Zacks Small Cap

Dogwood Therapeutics, Inc. (NASDAQ:DWTX) – Analysts at Zacks Small Cap issued their Q1 2025 earnings estimates for Dogwood Therapeutics in a research note issued to investors on Friday, April 4th. Zacks Small Cap analyst D. Bautz forecasts that the company will earn ($1.05) per share for the quarter. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share. Zacks Small Cap also issued estimates for Dogwood Therapeutics’ Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.00) EPS, Q4 2025 earnings at ($1.00) EPS and FY2027 earnings at ($2.33) EPS.

Dogwood Therapeutics (NASDAQ:DWTX) last posted its earnings results on Monday, March 31st. The company reported ($6.29) earnings per share for the quarter, missing the consensus estimate of ($1.49) by ($4.80).

Dogwood Therapeutics Price Performance

NASDAQ:DWTX opened at $3.61 on Monday. The company’s 50-day simple moving average is $6.80. Dogwood Therapeutics has a fifty-two week low of $1.62 and a fifty-two week high of $29.28. The company has a market cap of $4.81 million, a PE ratio of -0.55 and a beta of 1.99.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Geode Capital Management LLC acquired a new stake in Dogwood Therapeutics, Inc. (NASDAQ:DWTX) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 10,933 shares of the company’s stock, valued at approximately $27,000. Geode Capital Management LLC owned approximately 0.82% of Dogwood Therapeutics at the end of the most recent quarter. 9.05% of the stock is owned by institutional investors.

About Dogwood Therapeutics

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.